Literature DB >> 6369671

Provocation of skin graft rejection across murine class II differences by non--bone-marrow-derived cells.

P M Stuart, B Beck-Maier, R W Melvold.   

Abstract

We have evaluated the relative contribution of bone-marrow-derived cells to skin allograft immunogenicity in mice differing only at class II major histocompatibility genes by using bone marrow radiation chimeras as donors. The mouse strains used were C57BL/6Kh (B6) and B6.C-H-2bm12 (bm12), which differ only at at A beta gene of the I region of the mouse H-2 complex. Our results demonstrated that skin from (B6----bm12) chimeras was accepted by bm12 recipients and rejected by B6 mice in a manner indistinguishable from that of normal bm12 skin. Likewise, naive bm12 mice rejected (bm12----B6) chimeric skin and normal B6 skin equally well, and B6 animals accepted both types of skin grafts. Our data argues that the donor cell-type leading to graft rejection across limited I region differences is not of bone marrow origin, and that these cells must--at least under certain circumstances--express class II antigens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6369671     DOI: 10.1097/00007890-198404000-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Specificity of CD4+CD25+ regulatory T cell function in alloimmunity.

Authors:  Alberto Sánchez-Fueyo; Sigrid Sandner; Antje Habicht; Christophe Mariat; James Kenny; Nicolas Degauque; Xin Xiao Zheng; Terry B Strom; Laurence A Turka; Mohamed H Sayegh
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

2.  Transplantation of tail skin to study allogeneic CD4 T cell responses in mice.

Authors:  Mathias Schmaler; Maria A S Broggi; Simona W Rossi
Journal:  J Vis Exp       Date:  2014-07-25       Impact factor: 1.355

3.  CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.

Authors:  P M Stuart; T S Griffith; N Usui; J Pepose; X Yu; T A Ferguson
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.